



## **Test Update 826**

**Posted Date** 12/14/2022

**Effective Date** 01/31/2023

**Test Name** [Autoimmune Gastrointestinal Dysmotility Evaluation](#)

**Update Type** [Test Methodology Changed](#)

### **REVISIONS TO PROFILE AND REFLEX COMPONENTS**

#### **Gastrointestinal Dysmotility, Autoimmune Evaluation, Serum**

Order Code: MMLR

Reference Laboratory: Mayo GID2

Effective January 31, 2023, there will be additions and deletions to the profile and potential reflex tests for the Gastrointestinal Dysmotility, Autoimmune Evaluation, Serum referred to Mayo Clinic Laboratories as follows:

Testing to be added to Profile Information:

- APBIS: Adaptor Protein 3 Beta2 (AP3B2) Antibody, Tissue Immunofluorescence, Serum (CPT 86255)

Testing to be added to Reflex Tests:

- AN1TS: Antineuronal Nuclear Antibody-Type 1 (ANNA-1) Titer, Serum
- APBCS: Adaptor Protein 3 Beta2 (AP3B2) Antibody, Cell-Binding Assay, Serum
- APBTS: Adaptor Protein 3 Beta2 (AP3B2) Antibody, Tissue Immunofluorescence Titer, Serum
- CRMTS: Collapsin Response-Mediator Protein-5 (CRMP-5) Neuronal IgG Titer, Serum
- PC2TS: Purkinje Cell Cytoplasmic Antibody Type 2 (PCA-2) Titer, Serum

Testing to be removed from Reflex Tests:

- AMPCS: AMPA-Receptor Antibody, Cell Binding Assay, Serum
- AMPIS: AMPA-Receptor Antibody Titer Assay by Immunofluorescence, Serum
- AMPHS: Amphiphysin Antibody Assay, Serum
- AMIBS: Amphiphysin Antibody, Immunoblot, Serum
- GABCS: GABA-B-Receptor Antibody, Cell Binding Assay, Serum
- GABIS: GABA-B-Receptor Antibody Titer Assay by Immunofluorescence, Serum
- NMDCS: NMDA-Receptor Antibody, Cell Binding Assay, Serum

- NMDIS: NMDA-Receptor Antibody Titer Assay by Immunofluorescence, Serum
- PC1BS: Purkinje Cell Cytoplasmic Antibody-Type 1, Immunoblot, Serum
- PCABP: Purkinje Cell Cytoplasmic Antibody, Type 1 (PCA-1), Serum
- PCATR: Purkinje Cell Cytoplasmic Antibody, Type Tr, Serum
- PCTBS: Purkinje Cell Cytoplasmic Antibody-Type Tr, Immunoblot, Serum

[View PDF](#)